Phospho-OLIG2 (Ser10+Ser13+Ser14) Polyclonal Antibody

Product Specifications

Background

This gene encodes a basic helix-loop-helix transcription factor which is expressed in oligodendroglial tumors of the brain. The protein is an essential regulator of ventral neuroectodermal progenitor cell fate. The gene is involved in a chromosomal translocation t (14;21) (q11.2; q22) associated with T-cell acute lymphoblastic leukemia. Its chromosomal location is within a region of chromosome 21 which has been suggested to play a role in learning deficits associated with Down syndrome. [provided by RefSeq, Jul 2008]

Synonyms

Olig2 (phospho S10 + S13 + S14) ; p-Olig2 (phospho S10 + S13 + S14) ; Basic domain helix loop helix protein class B 1; Basic helix loop helix protein class B 1; BHLHB; bHLHB1; bHLHe19; Class B basic helix loop helix protein 1; Class B basic helix-loop-helix protein 1; class E basic helix loop helix protein 19; Class E basic helix-loop-helix protein 19; Human protein kinase C binding protein RACK17; Olig2; OLIG2_HUMAN; Oligo2 ; Oligodendrocyte lineage transcription factor 2; Oligodendrocyte specific bHLH transcription factor 2; Oligodendrocyte transcription factor 2; OTTHUMP00000067569; OTTHUMP00000067570; PRKCBP2; -binding protein RACK17; RACK17.

Gene ID

10215

Swiss Prot

Q13516

Modification Site

Ser10+Ser13+Ser14

Cellular Locus

Cytoplasm, Nucleus

Host

Rabbit

Cross Reactivity

Human

Target

Phospho-OLIG2 (Ser10+Ser13+Ser14)

Clonality

Polyclonal

Isotype

IgG

Conjugation

Unconjugated

Source

KLH conjugated synthesized phosphopeptide derived from human OLIG2 around the phosphorylation site of Ser10+Ser13+Ser14: VS (pS) RP (pS) (pS) PE

Applications

WB, FCM, IHC-P, IHC-F, IF

Purification

Purified by Protein A.

Concentration

1µg/µl

Dilution

WB (1:300-5000), FCM (1:20-100), IHC-P (1:200-400), IHC-F (1:100-500), IF ()

Buffer

0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Modification

Phosphorylation

Storage Conditions

Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.

Specificity

Expressed in the brain, in oligodendrocytes. Strongly expressed in oligodendrogliomas, while expression is weak to moderate in astrocytomas. Expression in glioblastomas highly variable.